Everett Cunningham Increases Stake in Arvinas, Inc. (ARVN)
Everett Cunningham purchased 22,714 shares of Arvinas, Inc. on June 24.
Key Points
- Everett Cunningham bought 22,714 shares of Arvinas, Inc. on June 24, 2026, with shares trading near $8.03 on Saturday.
- Arvinas, Inc. has a market cap of about $518 million, with a 52-week range between $6.06 and $14.51.
- Analysts from Stephens & Co., Barclays, and Citigroup maintain a buy rating, with price targets up to $24.
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
On June 24, 2026, Everett Cunningham purchased 22,714 shares of Arvinas, Inc. on the NasdaqGS under the ticker ARVN. This insider buying activity comes as shares traded near $8.03 on Saturday.
Insider Buying and Selling at Arvinas, Inc.
In addition to Everett Cunningham, several other insiders, including Linda Bain, Edward Moore Jr., Laurie Smaldone Alsup, Briggs Morrison, and Leslie Norwalk, also purchased shares of Arvinas, Inc. on June 24. Each transaction involved buying 15,527 or 22,714 shares, reflecting a coordinated buying effort.
Arvinas, Inc. Stock Down 12.9%
Shares of NasdaqGS:ARVN traded near $8.03 on Saturday. Arvinas, Inc. has a market cap of $518.1 million. The company is not currently profitable, so it has no meaningful P/E ratio. The stock has ranged from a 52-week low of $6.06 to a high of $14.51. Its 50-day moving average is $9.08, and the 200-day moving average is $10.67. Arvinas has a strong liquidity position with a current ratio of 5.44 and a quick ratio of 5.36, alongside a debt-to-equity ratio of 2.17.
$ARVN stock price
Daily closing prices, year to date. Not investment advice.
Analysts Set New Price Targets
On June 3, 2026, Stephens & Co. reiterated a buy rating for Arvinas, Inc. with a price target of $18. Barclays and BTIG maintained their buy ratings on May 13, with targets of $20 and $18, respectively. Citigroup also maintained its buy rating, setting the highest target at $24 on May 4. The consensus among 15 analysts is a buy rating, with a mean target price of $14.80.
About Arvinas, Inc.
Arvinas, Inc. is a biotechnology company based in New Haven, Connecticut. Founded in 2013, the company focuses on developing therapies to degrade disease-causing proteins using its PROTAC technology. Its pipeline includes treatments for various diseases, such as neurodegenerative disorders and cancers. Led by CEO Dr. Randy Teel, Arvinas collaborates with major pharmaceutical companies like Pfizer and Genentech.
Bottom Line
Insider buying by Everett Cunningham and others signals confidence in Arvinas, Inc. despite its current unprofitability. Investors often track such insider activities as they may hint at the company's potential. Keep in mind, however, that these transactions are backward-looking and may not reflect current positions.
Get Arvinas, Inc. alerts
New 13F filings, insider trades, and analyst moves on $ARVN, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.